Get the latest Science News and Discoveries

Insilico Medicine completes patient enrollment in its Phase IIa Study in China investigating INS018_055 for Idiopathic ... - EurekAlert


Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the completion of patient enrollment in a Phase IIa study (NCT05938920) in China, which is investigating the safety, tolerability, and preliminary efficacy of INS018_055 for idiopathic Pulmonary Fibrosis (IPF).

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of EurekAlert

EurekAlert

Photo of INS018_055

INS018_055

Photo of Insilico Medicine

Insilico Medicine

Related news:

News photo

Study reveals that market-ready beef cattle maintain meat quality on low-input diets for as long as 60 days - EurekAlert

News photo

Lab-grown muscles reveal mysteries of rare muscle diseases - EurekAlert

News photo

An active equalization strategy for series-co - EurekAlert